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Abstract
Background: In our recent study, we determined the cut-off value of CD20 expression at the level of 25 000
molecules of equivalent soluble fluorochrome (MESF) to be the predictor of response to rituximab containing
treatment in patients with B-cell lymphomas. In 17.5% of patients, who had the level of CD20 expression below the
cut-off value, the response to rituximab containing treatment was significantly worse than in the rest of the patients
with the level of CD20 expression above the cut-off value. The proportion of patients with low CD20 expression who
might not benefit from rituximab containing treatment was not necessarily representative. Therefore the aim of this
study was to quantify the CD20 expression in a larger series of patients with B-cell lymphomas which might allow us
to determine more reliably the proportion of patients with the CD20 expression below the cut-off.
Methods: Cytological samples of 64 diffuse large B-cell lymphomas (DLBCL), 56 follicular lymphomas (FL), 31 chronic
lymphocytic leukemias (CLL), 34 mantle cell lymphomas (MCL), 18 marginal zone lymphomas (MZL) and 15 B-cell
lymphomas unclassified were analyzed for CD20 expression by quantitative four-color flow cytometric measurements
using FACSCalibur flow cytometer (BD Biosciences).
Results: The range of CD20 expression in different B-cell lymphomas was very broad, varying from 2 737 to 115 623
MESF in CLL and 3 549 to 679 577 MESF in DLBCL. However, when we compared the CD20 expression in the groups
of patients with DLBCL, FL, MCL, MZL, CLL and B-cell lymphomas unclassified, it was found to be significantly lower
(p = 0.002) only in CLL but did not significantly differ in other lymphoma types (p = NS). Fifty-three out of 218
(24.3%) patients with B-cell lymphomas had the CD20 expression below the cut-off value.
Conclusions: The CD20 expression in CLL is significantly lower than in most histological types of mature B-cell
lymphomas in which it appears to be comparable. Approximately 25% of B-cell lymphoma patients have the CD20
expression below the cut-off value showing that the low CD20 expression might be more common than
presumed from our previous study.
Background
The study of CD20 expression (cluster of differentiation
antigens) in lymphoma cells is vital not only to establish
an accurate diagnosis but also to prepare an appropriate
plan of treatment with biological drugs [1,2]. As rituximab
is a biological drug most frequently used in the treatment
of B-cell lymphomas, the study of CD20 expression is
becoming increasingly important, in particular in the light
of most effective treatment planning and appropriate fol-
lowing-up of response to treatment. Even so, only few stu-
dies on CD20 expression in the patients with different
histology types of B-cell lymphoma have been so far
performed. In these few studies, it has been confirmed
that, in the majority of B-cell lymphomas, the CD20 anti-
gen is expressed on the surface of neoplastic cells; how-
ever, the intensity of CD20 expression varies by the type
of lymphoma and by the differentiation of lymphoma
B-cells. It is therefore assumed that the CD20 expression
is low in the cells of B-cell chronic lymphocytic leukemia
(CLL), while it is most intense in the cells of diffuse large
B-cell lymphoma (DLBCL) and of hairy cell leukemia
[3-5]; by contrast, it is only exceptionally aberrantly
expressed in the cells of multiple myeloma [6,7].
In addition, only sporadic studies have been investigat-
ing whether the level of CD20 expression is related to
the response to treatment with rituximab. The results of
two studies concluded recently showed indeed that the
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clinical outcome of patients with low CD20 expression
was worse than that of patients with high CD20 expres-
sion [8,9]. One of these studies was performed in our
laboratory. In this study, we determined the cut-off
value of CD20 expression at the level of 25 000 mole-
cules of equivalent soluble fluorochrome (MESF) to be
the predictor of response to rituximab containing treat-
ment in the patients with B-cell lymphomas. Namely,
the patients with low CD20 expression responded to
rituxmab containing treatment poorly or not at all com-
pared to patients with the CD20 expression above the
cut-off level. We also observed that slightly less than
one fifth of patients (17.5%) with B-cell lymphomas had
the CD20 expression below the cut-off value [9].
The purposes of the present study were firstly to
assess the level of CD20 expression in B-cell lymphomas
most frequently occurring in Slovenia where the inci-
dence of B-cell lymphoma is similar to that in Western
Europe and North America [10,11] and secondly to
determine the proportion of patients with the CD20
expression below the cut-off value of 25 000 MESF in a
larger series of patients.
Methods
Two hundred and eighteen patients diagnosed and treated
for primary or recurrent lymphoma at the Institute of
Oncology Ljubljana, Slovenia between 2003 and 2007 were
included in the study. By the time of cytological sampling,
none of the patients had been treated with rituximab.
In all patients, the primary or recurrent lymphoma had
been suspected clinically. Cytological examination with
flow cytometric immunophenotyping (FCI) was performed
to make or confirm the diagnosis of lymphoma. The cyto-
logical diagnosis was further verified by excisional biopsy
and histological examination in most cases. Only excep-
tionally, when the excisional biopsy could not be per-
formed, the cytological diagnosis was validated through
clinical follow-up. Among 218 patients included in the
study, 64 (29.4%) were diagnosed with DLBCL, 56 (25.7%)
follicular lymphoma (FL), 31 (14.2%) CLL, 18 (8.2%)
marginal zone lymphoma (MZL), 34 (15.6%) mantle cell
lymphoma (MCL) and 15 (6.9%) with B-cell lymphoma
unclassified.
Cytological examination and FCI
For 218 patients included in our study, 192 lymph node
fine needle aspiration biopsies (FNAB), 14 effusions,
7 cerebrospinal fluids, 1 bronchoalveolar lavages (BAL)
and 4 peripheral blood samples were obtained for cyto-
logical examination and FCI. From each sample, 2
smears were prepared for microscopic examination and
stained according to Giemsa and Papanicolaou method.
Cells of the rest of the sample were suspended in cell
media (4.5% bovine serum albumine, 0.45% EDTA in
phosphate buffer solution with 50 IE/ml of penicillin) to
prepare cell suspension for FCI. The absolute number of
cells in total volume of cell suspension was determined
in a Neubauer improved bright-line chamber. Samples
for four-color FCI were prepared according to the pro-
tocol adopted for cytological samples at the Institute of
Oncology, Ljubljana, Slovenia [12]. Antibodies by BD
Biosciences were mostly applied, except in case of the
antiCD52 antibody which was purchased from Serotec
Ltd (Table 1). The samples were first filtered through
50 μm pore filter. Then, 200000 cells and 1.5 ml buffer
(Cell Wash -BD Biosciences) were put in each test tube,
mixed and centrifuged for 5 minutes at 1500 turns per
minute. The supernatant was discarded and 3 or 5 μl of
antibodies were added according to the antibody panel
presented in Table 1. The samples were then mixed and
incubated in dark for 20 minutes. After incubation,
1.5 ml buffer (Cell Wash - BD Biosciences) was added
to the sample, mixed and centrifuged for 5 minutes at
1500 turns per minute. The supernatant was discarded
and 300 μl of buffer (Cell Wash -BD Biosciences) was
added [12]. The samples were measured with four-color
flow-cytometer FACSCalibur (BD Biosciences). Cell-
Quest software (BD Biosciences) was used for the acqui-
sition and analysis of the results. In each test tube, we
acquired 20 000 of CD45 or CD19 positive events
depending on antibody panel presented in Table 1. For
the analysis of the results, combined side scatter and
surface marker (CD45 or CD19) gating was used.
Flow cytometric quantification of CD20 expression
For the quantification of the CD20 expression, the
SPHERO Rainbow Calibration beads (Spherotech, Illinois,
USA) were employed. The SPHERO Rainbow Calibration
beads have been daily used in our laboratory for monitor-
ing the performance status of flow-cytometer since 2001.
Since these beads and the samples included in our study
have been always acquired applying equal flow-cytometric
settings, we could use the beads for the quantification of
CD20 expression. The PMT Linearity QC Record software
(Spherotech, Illinois, USA) was applied to determine the
relative level of CD20 expression in MESF [13].
Statistical analysis
Because the measurement variables did not meet the
normality assumption of an anova, we used the non-
parametric tests. Median, interquartile range and range
between minimal and maximal variable were used for
the description of CD20 expression. Kruskal Wallis and
Mann Whitney tests were used to assess the difference
in CD20 expression between the groups of patients with
different histological types of B-cell lymphomas.
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The research was approved by National Ethic Com-
mittee and was performed in compliance with the
Helsinki declaration.
Results
The CD20 expression in different B-cell lymphomas is
presented in Table 2. The highest median CD20 expres-
sion was observed in the patients with DLBCL and the
lowest in the patients with CLL. The range of CD20
expression in different B-cell lymphomas was wide, vary-
ing from 2 737 to 115 623 MESF in CLL and 3 549 to
679 577 MESF in DLBCL.
When the CD20 expressions in DLBCL, FL, MCL,
MZL, CLL and B-cell lymphomas unclassified were
compared, it was found to be significantly lower (p =
0.002) only in CLL (Figure 1), but not significantly dif-
ferent from other lymphoma types (p = NS).
In our study population, 24.3% of patients had the
level of CD20 expression below the cut-off value of
25 000 MESF. The highest percentage (74.2%) of
patients with the level of CD20 expression below the
cut-off value was noted in the group of patients with
CLL while the lowest (7.1%) was observed in the group
of patients with FL (Table 3, Figure 2). Table 3 also pre-
sents the number and the percentage of patients with
the CD20 expression below the cut-off value in the
present study compared to the results obtained in our
previous study (8)
Discussion
In the literature, there are only few data on the level of
CD20 expression in different types of B-cell lymphoma.
From the collected data, it may be concluded that the
types of B-cell lymphoma differ from each other by
CD20 expression; however, there is no clear evidence on
the range of these differences and the variability of
CD20 expression within each histological type of B-cell
lymphoma.
Ginaldi et al. were the first to report that the level of
CD20 expression in the patients with the leukemic form
of B-cell lymphoma is significantly the lowest in CLL
and the highest in hairy cell leukemia. No statistically
significant difference was observed between the CD20
expressions in B-cell prolymphocytic leukemia, splenic
MZL and MCL [3]. Similar results were reported by
Huh et al. and Olejniczak et al. who compared the
CD20 expressions in CLL, small B-cell lymphocytic
lymphoma, acute lymphoblastic leukemia, hairy cell leu-
kemia, DLBCL, FL, splenic MZL, and MCL [4,5]. Our
results are consistent with those obtained by Ginaldi,
Huh and Olejniczak, as they also show that the CD20
expression in the neoplastic cells of CLL is statistically
significantly lower than that in other B-cell lymphomas
included in our study (p = 0.002). We did not observe
any statistically significant differences between the CD20
expressions in DLBCL, FL, MCL, MZL and B-cell
lymphomas unclassified (p = NS). Though there was no
Table 1 Standard antibody panel used in the diagnostics of B-cell lymphomas
FITC PE PerCP/PerCP-Cy5.5 APC




mAbs Volume (μl) mAbs Volume
(μl)
1** CD3* 5 CD19* 5 CD45* 5 CD20 3
2** g1-FITC 5 g1-PE 5 CD19 5 g1-APC 3
3** Kappa* 5 Lambda* 5 CD19* 5 CD10 3
4** FMC7* 5 CD23* 5 CD19* 5 CD5 3
5 CD52 3 CD11 5 CD19 5 CD38 3
6 CD4* 5 CD8* 5 CD3* 5 CD2 3
mAbs monoclonal antibodies, FITC fluorescein isothiocyanate, PE phycoerythrin, PerCP peridinin chlorophyll protein, PerCP-Cy5.5 peridinin chlorophyll protein-
Cy5.5, APC-allophycocyanin, *BD Oncomark Reagents, ** when the samples were poorly cellular only test tubes 1-4 were applied.
Table 2 CD20 expression in different histological types of B-cell lymphomas
Histological type of B-cell lymphoma (N) CD20 expression (MESF)
Median Range IQR
DLBCL (64) 82 726 3 549 - 679 577 28 234 - 144 721
FL (56) 72 011 8 460 - 445 755 48 179 - 123 202
MCL (34) 66 375 8 826 - 423 799 39 725 - 99 915
MZL (18) 62 305 3 615 - 207 034 31 359 - 91 178
CLL (31) 14 064 2 737 - 115 623 8 275 - 26 855
NOS (15) 33 871 8 106 - 349 091 19 648 - 153 972
MESF...molecules of soluble fluorochrome, N...number of patients, IQR...interquartile range, DLBCL...diffuse large B-cell lymphoma, FL...follicular lymphoma, MCL...
mantle cell lymphoma, MZL...marginal zone lymphoma, CLL...chronic lymphocytic leukemia, NOS...B-cell lymphoma unclassified.
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statistically significant difference in the CD20 expres-
sions in DLBCL, FL, MCL, MZL and B-cell lymphomas
unclassified, the results of our study showed that the
CD20 expressions varied significantly within different
types of B-cell lymphomas. This may explain why the
response to treatment with rituximab of the patients
with the same type of lymphoma is so diverse.
Despite numerous clinical and preclinical studies on
rituximab, the treatment with this drug has not out-
grown its empirical use - we can confirm its efficacy
only in the patients in whom the CD20 expression was
determined in lymphoma cells, but we are not sure
whether the level of surface CD20 expression may be a
predictive factor, identifying the patients in whom the
treatment with rituximab would be efficient and those
in whom the use of this drug would be inefficient
[14-16]. Results of two similar studies, investigating
whether the level of CD20 expression is related to the
response to treatment with rituximab, have been
recently published. Johnson et al. have demonstrated
that the CD20 expression and response to treatment
with rituximab are connected. In the group of 272
patients with DLBCL treated with chemotherapy or
immunotherapy with rituximab, the survival of patients
with low CD20 expression was worse than that of
patients with high CD20 expression [9]. The results of
our most recent study are comparable to those of John-
son’s study. In the study performed on 114 patients with
different histological types of B-cell lymphoma, we
found a correlation between the level of CD20 expres-
sion and response to treatment with rituximab. We also
determined the cut-off value of CD20 expression at the
level of 25 000 molecules of equivalent soluble fluoro-
chrome (MESF) to be the predictor of response to ritux-
imab containing treatment in the patients with B-cell
lymphomas. This assumption was supported by our
findings that the patients with the level of CD20 expres-
sion above the cut-off value had a significantly longer
overall survival (p = 0.038) and a significantly higher
overall response rate (p < 0.001) than the patients with
the level of CD20 expression below the cut-off value.
Yet, we observed no significant difference in the
response duration between the two groups. By means of
the determined cut-off level of CD20 expression we esti-
mated that approximately one fifth of the B-cell
lymphoma patients with low CD20 expression will not
respond to rituximab containing treatment at all or will
not respond optimally [8].
Because this presumption was based on the results of
the study including only a smaller series of patients,
the proportion of patients with the CD20 expression
below the cut-off value might not be necessarily repre-
sentative. Namely, in the reported study, some B-cell
lymphoma groups consisted of only few patients, for
example of only 2 patients in the MZL group and of
only 5 patients in the CLL group. The reliability of the
proportion of patients having the CD20 expression
Figure 1 CD20 expression in different B-cell lymphomas.
MESF....molecules of soluble fluorochrome, CLL...chronic lymphocytic
leukemia, DLBCL...diffuse large B-cell lymphoma, FL...follicular
lymphoma, MCL...mantle cell lymphoma, MZL...marginal zone
lymphoma, NOS...B-cell lymphomas unclassified, NS...not significant.






below the cut-off value/





below the cut-off value/




Percentual difference in the
proportion of patients below the
cut-off value between the two
studies
DLBCL 11/64 17.2 6/42 14.3 2.9
FL 4/56 7.1 2/30 6.7 0.4
CLL 23/31 74.2 4/5 80.0 5.8
MCL 6/34 17.6 3/20 15.0 2.6
MZL 4/18 22.2 0/2 0 22.2
NOS 5/15 33.3 5/15 33.3 0
Total 53/218 24.3 20/114 17.5 6.8
DLBCL...diffuse large B-cell lymphoma, FL...follicular lymphoma, CLL chronic lympocytic leukemia, MCL...mantle cell lymphoma, MZL...marginal zone lymphoma,
NOS...B- cell lymphoma unclassified, text in bold...the results has been published in our previous study (M. Horvat et al. [8]).
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below the cut-off value in these two groups might
therefore be questionable.
Having expanded the study population, we detected that
almost 25% of B-cell lymphoma patients had the CD20
expression below the cut-off value of 25 000 MESF. This
proportion is higher than the 17.5% reported in our pre-
vious study. Among the patients with the CD20 expression
below the cut-off value, we found prevailingly the patients
with CLL (74.2%) and most infrequently the patients with
FL (7.1%). This distribution of low CD20 expression is for
the most part in concordance with our previous findings
[8]. However, the proportion of patients with the CD20
expression below the cut-off value varied in different B-cell
lymphoma groups when we expanded the study population.
It increased substantially in MZL (for as much as 22.2%)
and decreased in CLL patient group (for 5.8%). In the
groups of patients with DLBCL, FL and MCL, on the other
hand, we observed only a slight increase in the percentage
of patients having the CD20 expression below the cut-off
limit - the increase being between 0.4 to 2.9%. We believe,
that these changes are attributable to the altered number of
patients belonging to each of the B-cell lymphoma groups.
The results of our study indicate that the level of
CD20 expression is an important predictive factor for
the response to rituximab containing treatment. Still, we
believe that further studies on the intensity of CD20
expression should be carried out in a homogeneous
population of patients with identical histological types of
B-cell lymphoma.
Conclusions
CD20 expression in CLL is significantly lower than in
most histological types of mature B-cell lymphomas in
which it appears to be very comparable. Almost 25% of
B-cell lymphoma patients have the CD20 expression
below the cut-off value of 25 000 MESF which was
proposed to be the predictor of response to treatment
with rituximab. This proportion (24.3%) is higher than
the one reported in our previous study (17.5%).
Further studies are needed for the patients with every
histological type of B-cell lymphoma to confirm our
observations that the patients with low CD20 expres-
sion respond to rituximab containing treatment poorly
or not at all.
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